APO Research
Talk to an analyst

APO RESEARCH · REPORT

Synthetic Peptide Vaccine

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Synthetic Peptide Vaccine Market Outlook and Growth Opportunities 2026

30 December 2025206 pages

Choose your research edition.

Industry ResearchSynthetic Peptide Vaccine Industry Research Report 2026131 pages · $2,950 USDIndustry Growth & TrendsGlobal Synthetic Peptide Vaccine Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal Synthetic Peptide Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Synthetic Peptide Vaccine Market Outlook and Growth Opportunities 2026206 pages · $4,250 USDMarket Analysis & ForecastGlobal Synthetic Peptide Vaccine Market Analysis and Forecast 2026-2032205 pages · $4,950 USD

Market perspective

The global Synthetic Peptide Vaccine market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Synthetic Peptide Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Synthetic Peptide Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Synthetic Peptide Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Synthetic Peptide Vaccine market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Synthetic Peptide Vaccine market include Merck, Targovax, TapImmune, Sumitomo Dainippon Pharma, Spotlight Innovation, Pharmasyntez, Peptech, OncoTherapy Science and Lytix Biopharma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Synthetic Peptide Vaccine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Synthetic Peptide Vaccine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Synthetic Peptide Vaccine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Synthetic Peptide Vaccine market size, projected growth trends, production technologies, key applications, and end-use industries.

Synthetic Peptide Vaccine Segment by Company

Merck

Targovax

TapImmune

Sumitomo Dainippon Pharma

Spotlight Innovation

Pharmasyntez

Peptech

OncoTherapy Science

Lytix Biopharma

ISA Pharmaceuticals

ImmunoCellular Therapeutics

Immatics biotechnologies

Celgene Corporation

Benovus Bio

Artificial Cell Technologies

Apitope Technology

Antigen Express

Anergis

Synthetic Peptide Vaccine Segment by Type

Solution Phase Synthesis (SPS)

Solid Phase Peptide Synthesis (SPPS)

Synthetic Peptide Vaccine Segment by Application

Lung Cancer

Prostate Cancer

Breast Cancer

Gastric Cancer

Pancreatic Cancer

Others

Synthetic Peptide Vaccine Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Synthetic Peptide Vaccine status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Synthetic Peptide Vaccine market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Synthetic Peptide Vaccine significant trends, drivers, influence factors in global and regions.

6. To analyze Synthetic Peptide Vaccine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Synthetic Peptide Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Synthetic Peptide Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Synthetic Peptide Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Synthetic Peptide Vaccine market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Synthetic Peptide Vaccine industry.

Chapter 3: Detailed analysis of Synthetic Peptide Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Synthetic Peptide Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Synthetic Peptide Vaccine in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Synthetic Peptide Vaccine Industry Trends Table 2. Synthetic Peptide Vaccine Industry Drivers Table 3. Synthetic Peptide Vaccine Industry Opportunities and Challenges Table 4. Synthetic Peptide Vaccine Industry Restraints Table 5. Global Synthetic Peptide Vaccine Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Synthetic Peptide Vaccine Revenue Share by Company (2021-2026) Table 7. Global Synthetic Peptide Vaccine Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Synthetic Peptide Vaccine Sales Volume Share by Company (2021-2026) Table 9. Global Synthetic Peptide Vaccine Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Synthetic Peptide Vaccine Company Ranking, (2024-2026) & (USD Million) Table 11. Global Synthetic Peptide Vaccine Key Company Manufacturing Base & Headquarters Table 12. Global Synthetic Peptide Vaccine Company, Product Type & Application Table 13. Global Synthetic Peptide Vaccine Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Synthetic Peptide Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Solution Phase Synthesis (SPS) Table 18. Significant Companies of Solid Phase Peptide Synthesis (SPPS) Table 19. Global Synthetic Peptide Vaccine Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Synthetic Peptide Vaccine Sales Volume by Type (2021-2026) & (K Units) Table 21. Global Synthetic Peptide Vaccine Sales Volume by Type (2027-2032) & (K Units) Table 22. Global Synthetic Peptide Vaccine Sales Volume Share by Type (2021-2026) Table 23. Global Synthetic Peptide Vaccine Sales Volume Share by Type (2027-2032) Table 24. Global Synthetic Peptide Vaccine Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Synthetic Peptide Vaccine Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Synthetic Peptide Vaccine Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Synthetic Peptide Vaccine Sales Value Share by Type (2021-2026) Table 28. Global Synthetic Peptide Vaccine Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Lung Cancer Table 30. Significant Companies of Prostate Cancer Table 31. Significant Companies of Breast Cancer Table 32. Significant Companies of Gastric Cancer Table 33. Significant Companies of Pancreatic Cancer Table 34. Significant Companies of Others Table 35. Global Synthetic Peptide Vaccine Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 36. Global Synthetic Peptide Vaccine Sales Volume by Application (2021-2026) & (K Units) Table 37. Global Synthetic Peptide Vaccine Sales Volume by Application (2027-2032) & (K Units) Table 38. Global Synthetic Peptide Vaccine Sales Volume Share by Application (2021-2026) Table 39. Global Synthetic Peptide Vaccine Sales Volume Share by Application (2027-2032) Table 40. Global Synthetic Peptide Vaccine Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 41. Global Synthetic Peptide Vaccine Sales Value by Application (2021-2026) & (US$ Million) Table 42. Global Synthetic Peptide Vaccine Sales Value by Application (2027-2032) & (US$ Million) Table 43. Global Synthetic Peptide Vaccine Sales Value Share by Application (2021-2026) Table 44. Global Synthetic Peptide Vaccine Sales Value Share by Application (2027-2032) Table 45. Global Synthetic Peptide Vaccine Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 46. Global Synthetic Peptide Vaccine Sales by Region (2021-2026) & (K Units) Table 47. Global Synthetic Peptide Vaccine Sales Market Share by Region (2021-2026) Table 48. Global Synthetic Peptide Vaccine Sales by Region (2027-2032) & (K Units) Table 49. Global Synthetic Peptide Vaccine Sales Market Share by Region (2027-2032) Table 50. Global Synthetic Peptide Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 51. Global Synthetic Peptide Vaccine Sales Value by Region (2021-2026) & (US$ Million) Table 52. Global Synthetic Peptide Vaccine Sales Value Share by Region (2021-2026) Table 53. Global Synthetic Peptide Vaccine Sales Value by Region (2027-2032) & (US$ Million) Table 54. Global Synthetic Peptide Vaccine Sales Value Share by Region (2027-2032) Table 55. Global Synthetic Peptide Vaccine Market Average Price (US$/Unit) by Region (2021-2026) Table 56. Global Synthetic Peptide Vaccine Market Average Price (US$/Unit) by Region (2027-2032) Table 57. Global Synthetic Peptide Vaccine Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 58. Global Synthetic Peptide Vaccine Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Synthetic Peptide Vaccine Sales by Country (2021-2026) & (K Units) Table 60. Global Synthetic Peptide Vaccine Sales Market Share by Country (2021-2026) Table 61. Global Synthetic Peptide Vaccine Sales by Country (2027-2032) & (K Units) Table 62. Global Synthetic Peptide Vaccine Sales Market Share by Country (2027-2032) Table 63. Global Synthetic Peptide Vaccine Sales Value by Country (2021-2026) & (US$ Million) Table 64. Global Synthetic Peptide Vaccine Sales Value Market Share by Country (2021-2026) Table 65. Global Synthetic Peptide Vaccine Sales Value by Country (2027-2032) & (US$ Million) Table 66. Global Synthetic Peptide Vaccine Sales Value Market Share by Country (2027-2032) Table 67. Merck Company Information Table 68. Merck Business Overview Table 69. Merck Synthetic Peptide Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 70. Merck Synthetic Peptide Vaccine Product Portfolio Table 71. Merck Recent Development Table 72. Targovax Company Information Table 73. Targovax Business Overview Table 74. Targovax Synthetic Peptide Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 75. Targovax Synthetic Peptide Vaccine Product Portfolio Table 76. Targovax Recent Development Table 77. TapImmune Company Information Table 78. TapImmune Business Overview Table 79. TapImmune Synthetic Peptide Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 80. TapImmune Synthetic Peptide Vaccine Product Portfolio Table 81. TapImmune Recent Development Table 82. Sumitomo Dainippon Pharma Company Information Table 83. Sumitomo Dainippon Pharma Business Overview Table 84. Sumitomo Dainippon Pharma Synthetic Peptide Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 85. Sumitomo Dainippon Pharma Synthetic Peptide Vaccine Product Portfolio Table 86. Sumitomo Dainippon Pharma Recent Development Table 87. Spotlight Innovation Company Information Table 88. Spotlight Innovation Business Overview Table 89. Spotlight Innovation Synthetic Peptide Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. Spotlight Innovation Synthetic Peptide Vaccine Product Portfolio Table 91. Spotlight Innovation Recent Development Table 92. Pharmasyntez Company Information Table 93. Pharmasyntez Business Overview Table 94. Pharmasyntez Synthetic Peptide Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Pharmasyntez Synthetic Peptide Vaccine Product Portfolio Table 96. Pharmasyntez Recent Development Table 97. Peptech Company Information Table 98. Peptech Business Overview Table 99. Peptech Synthetic Peptide Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. Peptech Synthetic Peptide Vaccine Product Portfolio Table 101. Peptech Recent Development Table 102. OncoTherapy Science Company Information Table 103. OncoTherapy Science Business Overview Table 104. OncoTherapy Science Synthetic Peptide Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. OncoTherapy Science Synthetic Peptide Vaccine Product Portfolio Table 106. OncoTherapy Science Recent Development Table 107. Lytix Biopharma Company Information Table 108. Lytix Biopharma Business Overview Table 109. Lytix Biopharma Synthetic Peptide Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 110. Lytix Biopharma Synthetic Peptide Vaccine Product Portfolio Table 111. Lytix Biopharma Recent Development Table 112. ISA Pharmaceuticals Company Information Table 113. ISA Pharmaceuticals Business Overview Table 114. ISA Pharmaceuticals Synthetic Peptide Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 115. ISA Pharmaceuticals Synthetic Peptide Vaccine Product Portfolio Table 116. ISA Pharmaceuticals Recent Development Table 117. ImmunoCellular Therapeutics Company Information Table 118. ImmunoCellular Therapeutics Business Overview Table 119. ImmunoCellular Therapeutics Synthetic Peptide Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 120. ImmunoCellular Therapeutics Synthetic Peptide Vaccine Product Portfolio Table 121. ImmunoCellular Therapeutics Recent Development Table 122. Immatics biotechnologies Company Information Table 123. Immatics biotechnologies Business Overview Table 124. Immatics biotechnologies Synthetic Peptide Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 125. Immatics biotechnologies Synthetic Peptide Vaccine Product Portfolio Table 126. Immatics biotechnologies Recent Development Table 127. Celgene Corporation Company Information Table 128. Celgene Corporation Business Overview Table 129. Celgene Corporation Synthetic Peptide Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 130. Celgene Corporation Synthetic Peptide Vaccine Product Portfolio Table 131. Celgene Corporation Recent Development Table 132. Benovus Bio Company Information Table 133. Benovus Bio Business Overview Table 134. Benovus Bio Synthetic Peptide Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 135. Benovus Bio Synthetic Peptide Vaccine Product Portfolio Table 136. Benovus Bio Recent Development Table 137. Artificial Cell Technologies Company Information Table 138. Artificial Cell Technologies Business Overview Table 139. Artificial Cell Technologies Synthetic Peptide Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 140. Artificial Cell Technologies Synthetic Peptide Vaccine Product Portfolio Table 141. Artificial Cell Technologies Recent Development Table 142. Apitope Technology Company Information Table 143. Apitope Technology Business Overview Table 144. Apitope Technology Synthetic Peptide Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 145. Apitope Technology Synthetic Peptide Vaccine Product Portfolio Table 146. Apitope Technology Recent Development Table 147. Antigen Express Company Information Table 148. Antigen Express Business Overview Table 149. Antigen Express Synthetic Peptide Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 150. Antigen Express Synthetic Peptide Vaccine Product Portfolio Table 151. Antigen Express Recent Development Table 152. Anergis Company Information Table 153. Anergis Business Overview Table 154. Anergis Synthetic Peptide Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 155. Anergis Synthetic Peptide Vaccine Product Portfolio Table 156. Anergis Recent Development Table 157. Key Raw Materials Table 158. Raw Materials Key Suppliers Table 159. Synthetic Peptide Vaccine Distributors List Table 160. Synthetic Peptide Vaccine Customers List Table 161. Research Programs/Design for This Report Table 162. Authors List of This Report Table 163. Secondary Sources Table 164. Primary Sources List of Figures Figure 1. Synthetic Peptide Vaccine Product Image Figure 2. Global Synthetic Peptide Vaccine Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Synthetic Peptide Vaccine Sales Value (2021-2032) & (US$ Million) Figure 4. Global Synthetic Peptide Vaccine Sales (2021-2032) & (K Units) Figure 5. Global Synthetic Peptide Vaccine Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Synthetic Peptide Vaccine Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Solution Phase Synthesis (SPS) Image Figure 10. Solid Phase Peptide Synthesis (SPPS) Image Figure 11. Global Synthetic Peptide Vaccine Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Synthetic Peptide Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Synthetic Peptide Vaccine Sales Volume Share by Type (2021-2032) Figure 14. Global Synthetic Peptide Vaccine Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Synthetic Peptide Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Synthetic Peptide Vaccine Sales Value Share by Type (2021-2032) Figure 17. Lung Cancer Image Figure 18. Prostate Cancer Image Figure 19. Breast Cancer Image Figure 20. Gastric Cancer Image Figure 21. Pancreatic Cancer Image Figure 22. Others Image Figure 23. Global Synthetic Peptide Vaccine Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 24. Global Synthetic Peptide Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 25. Global Synthetic Peptide Vaccine Sales Volume Share by Application (2021-2032) Figure 26. Global Synthetic Peptide Vaccine Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 27. Global Synthetic Peptide Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 28. Global Synthetic Peptide Vaccine Sales Value Share by Application (2021-2032) Figure 29. Global Synthetic Peptide Vaccine Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 30. Global Synthetic Peptide Vaccine Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 31. Global Synthetic Peptide Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 32. Global Synthetic Peptide Vaccine Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 33. North America Synthetic Peptide Vaccine Sales Value (2021-2032) & (US$ Million) Figure 34. North America Synthetic Peptide Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Europe Synthetic Peptide Vaccine Sales Value (2021-2032) & (US$ Million) Figure 36. Europe Synthetic Peptide Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Asia-Pacific Synthetic Peptide Vaccine Sales Value (2021-2032) & (US$ Million) Figure 38. Asia-Pacific Synthetic Peptide Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 39. South America Synthetic Peptide Vaccine Sales Value (2021-2032) & (US$ Million) Figure 40. South America Synthetic Peptide Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 41. Middle East & Africa Synthetic Peptide Vaccine Sales Value (2021-2032) & (US$ Million) Figure 42. Middle East & Africa Synthetic Peptide Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 43. USA Synthetic Peptide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. USA Synthetic Peptide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. USA Synthetic Peptide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Canada Synthetic Peptide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Canada Synthetic Peptide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Canada Synthetic Peptide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Mexico Synthetic Peptide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Mexico Synthetic Peptide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Mexico Synthetic Peptide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Germany Synthetic Peptide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Germany Synthetic Peptide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Germany Synthetic Peptide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. France Synthetic Peptide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. France Synthetic Peptide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. France Synthetic Peptide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. U.K. Synthetic Peptide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. U.K. Synthetic Peptide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. U.K. Synthetic Peptide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Italy Synthetic Peptide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Italy Synthetic Peptide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Italy Synthetic Peptide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Spain Synthetic Peptide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Spain Synthetic Peptide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Spain Synthetic Peptide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Russia Synthetic Peptide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Russia Synthetic Peptide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Russia Synthetic Peptide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Netherlands Synthetic Peptide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Netherlands Synthetic Peptide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Netherlands Synthetic Peptide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. Nordic Countries Synthetic Peptide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. Nordic Countries Synthetic Peptide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. Nordic Countries Synthetic Peptide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. China Synthetic Peptide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. China Synthetic Peptide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. China Synthetic Peptide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Japan Synthetic Peptide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Japan Synthetic Peptide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Japan Synthetic Peptide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. South Korea Synthetic Peptide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. South Korea Synthetic Peptide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. South Korea Synthetic Peptide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. India Synthetic Peptide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. India Synthetic Peptide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. India Synthetic Peptide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Australia Synthetic Peptide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Australia Synthetic Peptide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Australia Synthetic Peptide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Southeast Asia Synthetic Peptide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Southeast Asia Synthetic Peptide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Southeast Asia Synthetic Peptide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Brazil Synthetic Peptide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Brazil Synthetic Peptide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Brazil Synthetic Peptide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Argentina Synthetic Peptide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Argentina Synthetic Peptide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Argentina Synthetic Peptide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Chile Synthetic Peptide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Chile Synthetic Peptide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Chile Synthetic Peptide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Colombia Synthetic Peptide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Colombia Synthetic Peptide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Colombia Synthetic Peptide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Peru Synthetic Peptide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Peru Synthetic Peptide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Peru Synthetic Peptide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Synthetic Peptide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Saudi Arabia Synthetic Peptide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Saudi Arabia Synthetic Peptide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Israel Synthetic Peptide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Israel Arabia Synthetic Peptide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Israel Arabia Synthetic Peptide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. UAE Synthetic Peptide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. UAE Synthetic Peptide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. UAE Synthetic Peptide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Turkey Synthetic Peptide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Turkey Synthetic Peptide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Turkey Synthetic Peptide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Iran Synthetic Peptide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Iran Synthetic Peptide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Iran Synthetic Peptide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Egypt Synthetic Peptide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 125. Egypt Synthetic Peptide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 126. Egypt Synthetic Peptide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 127. Synthetic Peptide Vaccine Value Chain Figure 128. Manufacturing Cost Structure Figure 129. Synthetic Peptide Vaccine Sales Mode & Process Figure 130. Direct Comparison with Distribution Share Figure 131. Distributors Profiles Figure 132. Years Considered Figure 133. Research Process Figure 134. Key Executives Interviewed

Scope & coverage.

Types
  • Solution Phase Synthesis (SPS)
  • Solid Phase Peptide Synthesis (SPPS)
Applications
  • Lung Cancer
  • Prostate Cancer
  • Breast Cancer
  • Gastric Cancer
  • Pancreatic Cancer
  • Others
Companies covered
  • Merck
  • Targovax
  • TapImmune
  • Sumitomo Dainippon Pharma
  • Spotlight Innovation
  • Pharmasyntez
  • Peptech
  • OncoTherapy Science
  • Lytix Biopharma
  • ISA Pharmaceuticals
  • ImmunoCellular Therapeutics
  • Immatics biotechnologies
  • Celgene Corporation
  • Benovus Bio
  • Artificial Cell Technologies
  • Apitope Technology
  • Antigen Express
  • Anergis

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Synthetic Peptide Vaccine Sales Value (2021-2032)
  4. 1.2.2 Global Synthetic Peptide Vaccine Sales Volume (2021-2032)
  5. 1.2.3 Global Synthetic Peptide Vaccine Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Synthetic Peptide Vaccine Market Dynamics
  1. 2.1 Synthetic Peptide Vaccine Industry Trends
  2. 2.2 Synthetic Peptide Vaccine Industry Drivers
  3. 2.3 Synthetic Peptide Vaccine Industry Opportunities and Challenges
  4. 2.4 Synthetic Peptide Vaccine Industry Restraints
3 Synthetic Peptide Vaccine Market by Company
  1. 3.1 Global Synthetic Peptide Vaccine Company Revenue Ranking in 2025
  2. 3.2 Global Synthetic Peptide Vaccine Revenue by Company (2021-2026)
  3. 3.3 Global Synthetic Peptide Vaccine Sales Volume by Company (2021-2026)
  4. 3.4 Global Synthetic Peptide Vaccine Average Price by Company (2021-2026)
  5. 3.5 Global Synthetic Peptide Vaccine Company Ranking (2024-2026)
  6. 3.6 Global Synthetic Peptide Vaccine Company Manufacturing Base and Headquarters
  7. 3.7 Global Synthetic Peptide Vaccine Company Product Type and Application
  8. 3.8 Global Synthetic Peptide Vaccine Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Synthetic Peptide Vaccine Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Synthetic Peptide Vaccine Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Synthetic Peptide Vaccine Market by Type
  1. 4.1 Synthetic Peptide Vaccine Type Introduction
  2. 4.1.1 Solution Phase Synthesis (SPS)
  3. 4.1.2 Solid Phase Peptide Synthesis (SPPS)
  4. 4.2 Global Synthetic Peptide Vaccine Sales Volume by Type
  5. 4.2.1 Global Synthetic Peptide Vaccine Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Synthetic Peptide Vaccine Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Synthetic Peptide Vaccine Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Synthetic Peptide Vaccine Sales Value by Type
  9. 4.3.1 Global Synthetic Peptide Vaccine Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Synthetic Peptide Vaccine Sales Value by Type (2021-2032)
  11. 4.3.3 Global Synthetic Peptide Vaccine Sales Value Share by Type (2021-2032)
5 Synthetic Peptide Vaccine Market by Application
  1. 5.1 Synthetic Peptide Vaccine Application Introduction
  2. 5.1.1 Lung Cancer
  3. 5.1.2 Prostate Cancer
  4. 5.1.3 Breast Cancer
  5. 5.1.4 Gastric Cancer
  6. 5.1.5 Pancreatic Cancer
  7. 5.1.6 Others
  8. 5.2 Global Synthetic Peptide Vaccine Sales Volume by Application
  9. 5.2.1 Global Synthetic Peptide Vaccine Sales Volume by Application (2021 VS 2025 VS 2032)
  10. 5.2.2 Global Synthetic Peptide Vaccine Sales Volume by Application (2021-2032)
  11. 5.2.3 Global Synthetic Peptide Vaccine Sales Volume Share by Application (2021-2032)
  12. 5.3 Global Synthetic Peptide Vaccine Sales Value by Application
  13. 5.3.1 Global Synthetic Peptide Vaccine Sales Value by Application (2021 VS 2025 VS 2032)
  14. 5.3.2 Global Synthetic Peptide Vaccine Sales Value by Application (2021-2032)
  15. 5.3.3 Global Synthetic Peptide Vaccine Sales Value Share by Application (2021-2032)
6 Synthetic Peptide Vaccine Regional Sales and Value Analysis
  1. 6.1 Global Synthetic Peptide Vaccine Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Synthetic Peptide Vaccine Sales by Region (2021-2032)
  3. 6.2.1 Global Synthetic Peptide Vaccine Sales by Region: 2021-2026
  4. 6.2.2 Global Synthetic Peptide Vaccine Sales by Region (2027-2032)
  5. 6.3 Global Synthetic Peptide Vaccine Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Synthetic Peptide Vaccine Sales Value by Region (2021-2032)
  7. 6.4.1 Global Synthetic Peptide Vaccine Sales Value by Region: 2021-2026
  8. 6.4.2 Global Synthetic Peptide Vaccine Sales Value by Region (2027-2032)
  9. 6.5 Global Synthetic Peptide Vaccine Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Synthetic Peptide Vaccine Sales Value (2021-2032)
  12. 6.6.2 North America Synthetic Peptide Vaccine Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Synthetic Peptide Vaccine Sales Value (2021-2032)
  15. 6.7.2 Europe Synthetic Peptide Vaccine Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Synthetic Peptide Vaccine Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Synthetic Peptide Vaccine Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Synthetic Peptide Vaccine Sales Value (2021-2032)
  21. 6.9.2 South America Synthetic Peptide Vaccine Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Synthetic Peptide Vaccine Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Synthetic Peptide Vaccine Sales Value Share by Country, 2025 VS 2032
7 Synthetic Peptide Vaccine Country-level Sales and Value Analysis
  1. 7.1 Global Synthetic Peptide Vaccine Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Synthetic Peptide Vaccine Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Synthetic Peptide Vaccine Sales by Country (2021-2032)
  4. 7.3.1 Global Synthetic Peptide Vaccine Sales by Country (2021-2026)
  5. 7.3.2 Global Synthetic Peptide Vaccine Sales by Country (2027-2032)
  6. 7.4 Global Synthetic Peptide Vaccine Sales Value by Country (2021-2032)
  7. 7.4.1 Global Synthetic Peptide Vaccine Sales Value by Country (2021-2026)
  8. 7.4.2 Global Synthetic Peptide Vaccine Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Synthetic Peptide Vaccine Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Synthetic Peptide Vaccine Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Synthetic Peptide Vaccine Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Synthetic Peptide Vaccine Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Synthetic Peptide Vaccine Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Synthetic Peptide Vaccine Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Synthetic Peptide Vaccine Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Synthetic Peptide Vaccine Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Synthetic Peptide Vaccine Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Synthetic Peptide Vaccine Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Synthetic Peptide Vaccine Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Synthetic Peptide Vaccine Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Synthetic Peptide Vaccine Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Synthetic Peptide Vaccine Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Synthetic Peptide Vaccine Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Synthetic Peptide Vaccine Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Synthetic Peptide Vaccine Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Synthetic Peptide Vaccine Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Synthetic Peptide Vaccine Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Synthetic Peptide Vaccine Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Synthetic Peptide Vaccine Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Synthetic Peptide Vaccine Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Synthetic Peptide Vaccine Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Synthetic Peptide Vaccine Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Synthetic Peptide Vaccine Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Synthetic Peptide Vaccine Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Synthetic Peptide Vaccine Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Synthetic Peptide Vaccine Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Synthetic Peptide Vaccine Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Synthetic Peptide Vaccine Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Synthetic Peptide Vaccine Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Synthetic Peptide Vaccine Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Synthetic Peptide Vaccine Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Synthetic Peptide Vaccine Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Synthetic Peptide Vaccine Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Synthetic Peptide Vaccine Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Synthetic Peptide Vaccine Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Synthetic Peptide Vaccine Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Synthetic Peptide Vaccine Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Synthetic Peptide Vaccine Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Synthetic Peptide Vaccine Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Synthetic Peptide Vaccine Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Synthetic Peptide Vaccine Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Synthetic Peptide Vaccine Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Synthetic Peptide Vaccine Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Synthetic Peptide Vaccine Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Synthetic Peptide Vaccine Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Synthetic Peptide Vaccine Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Synthetic Peptide Vaccine Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Synthetic Peptide Vaccine Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Synthetic Peptide Vaccine Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Synthetic Peptide Vaccine Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Synthetic Peptide Vaccine Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Synthetic Peptide Vaccine Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Synthetic Peptide Vaccine Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Synthetic Peptide Vaccine Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Synthetic Peptide Vaccine Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Synthetic Peptide Vaccine Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Synthetic Peptide Vaccine Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Synthetic Peptide Vaccine Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Synthetic Peptide Vaccine Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Synthetic Peptide Vaccine Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Synthetic Peptide Vaccine Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Synthetic Peptide Vaccine Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Synthetic Peptide Vaccine Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Synthetic Peptide Vaccine Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Synthetic Peptide Vaccine Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Synthetic Peptide Vaccine Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Synthetic Peptide Vaccine Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Synthetic Peptide Vaccine Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Synthetic Peptide Vaccine Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Synthetic Peptide Vaccine Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Synthetic Peptide Vaccine Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Synthetic Peptide Vaccine Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Synthetic Peptide Vaccine Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Synthetic Peptide Vaccine Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Synthetic Peptide Vaccine Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Synthetic Peptide Vaccine Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Synthetic Peptide Vaccine Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Synthetic Peptide Vaccine Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Synthetic Peptide Vaccine Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Synthetic Peptide Vaccine Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Synthetic Peptide Vaccine Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Synthetic Peptide Vaccine Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Merck
  2. 8.1.1 Merck Company Information
  3. 8.1.2 Merck Business Overview
  4. 8.1.3 Merck Synthetic Peptide Vaccine Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Merck Synthetic Peptide Vaccine Product Portfolio
  6. 8.1.5 Merck Recent Developments
  7. 8.2 Targovax
  8. 8.2.1 Targovax Company Information
  9. 8.2.2 Targovax Business Overview
  10. 8.2.3 Targovax Synthetic Peptide Vaccine Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Targovax Synthetic Peptide Vaccine Product Portfolio
  12. 8.2.5 Targovax Recent Developments
  13. 8.3 TapImmune
  14. 8.3.1 TapImmune Company Information
  15. 8.3.2 TapImmune Business Overview
  16. 8.3.3 TapImmune Synthetic Peptide Vaccine Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 TapImmune Synthetic Peptide Vaccine Product Portfolio
  18. 8.3.5 TapImmune Recent Developments
  19. 8.4 Sumitomo Dainippon Pharma
  20. 8.4.1 Sumitomo Dainippon Pharma Company Information
  21. 8.4.2 Sumitomo Dainippon Pharma Business Overview
  22. 8.4.3 Sumitomo Dainippon Pharma Synthetic Peptide Vaccine Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Sumitomo Dainippon Pharma Synthetic Peptide Vaccine Product Portfolio
  24. 8.4.5 Sumitomo Dainippon Pharma Recent Developments
  25. 8.5 Spotlight Innovation
  26. 8.5.1 Spotlight Innovation Company Information
  27. 8.5.2 Spotlight Innovation Business Overview
  28. 8.5.3 Spotlight Innovation Synthetic Peptide Vaccine Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Spotlight Innovation Synthetic Peptide Vaccine Product Portfolio
  30. 8.5.5 Spotlight Innovation Recent Developments
  31. 8.6 Pharmasyntez
  32. 8.6.1 Pharmasyntez Company Information
  33. 8.6.2 Pharmasyntez Business Overview
  34. 8.6.3 Pharmasyntez Synthetic Peptide Vaccine Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Pharmasyntez Synthetic Peptide Vaccine Product Portfolio
  36. 8.6.5 Pharmasyntez Recent Developments
  37. 8.7 Peptech
  38. 8.7.1 Peptech Company Information
  39. 8.7.2 Peptech Business Overview
  40. 8.7.3 Peptech Synthetic Peptide Vaccine Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Peptech Synthetic Peptide Vaccine Product Portfolio
  42. 8.7.5 Peptech Recent Developments
  43. 8.8 OncoTherapy Science
  44. 8.8.1 OncoTherapy Science Company Information
  45. 8.8.2 OncoTherapy Science Business Overview
  46. 8.8.3 OncoTherapy Science Synthetic Peptide Vaccine Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 OncoTherapy Science Synthetic Peptide Vaccine Product Portfolio
  48. 8.8.5 OncoTherapy Science Recent Developments
  49. 8.9 Lytix Biopharma
  50. 8.9.1 Lytix Biopharma Company Information
  51. 8.9.2 Lytix Biopharma Business Overview
  52. 8.9.3 Lytix Biopharma Synthetic Peptide Vaccine Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Lytix Biopharma Synthetic Peptide Vaccine Product Portfolio
  54. 8.9.5 Lytix Biopharma Recent Developments
  55. 8.10 ISA Pharmaceuticals
  56. 8.10.1 ISA Pharmaceuticals Company Information
  57. 8.10.2 ISA Pharmaceuticals Business Overview
  58. 8.10.3 ISA Pharmaceuticals Synthetic Peptide Vaccine Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 ISA Pharmaceuticals Synthetic Peptide Vaccine Product Portfolio
  60. 8.10.5 ISA Pharmaceuticals Recent Developments
  61. 8.11 ImmunoCellular Therapeutics
  62. 8.11.1 ImmunoCellular Therapeutics Company Information
  63. 8.11.2 ImmunoCellular Therapeutics Business Overview
  64. 8.11.3 ImmunoCellular Therapeutics Synthetic Peptide Vaccine Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 ImmunoCellular Therapeutics Synthetic Peptide Vaccine Product Portfolio
  66. 8.11.5 ImmunoCellular Therapeutics Recent Developments
  67. 8.12 Immatics biotechnologies
  68. 8.12.1 Immatics biotechnologies Company Information
  69. 8.12.2 Immatics biotechnologies Business Overview
  70. 8.12.3 Immatics biotechnologies Synthetic Peptide Vaccine Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Immatics biotechnologies Synthetic Peptide Vaccine Product Portfolio
  72. 8.12.5 Immatics biotechnologies Recent Developments
  73. 8.13 Celgene Corporation
  74. 8.13.1 Celgene Corporation Company Information
  75. 8.13.2 Celgene Corporation Business Overview
  76. 8.13.3 Celgene Corporation Synthetic Peptide Vaccine Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Celgene Corporation Synthetic Peptide Vaccine Product Portfolio
  78. 8.13.5 Celgene Corporation Recent Developments
  79. 8.14 Benovus Bio
  80. 8.14.1 Benovus Bio Company Information
  81. 8.14.2 Benovus Bio Business Overview
  82. 8.14.3 Benovus Bio Synthetic Peptide Vaccine Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Benovus Bio Synthetic Peptide Vaccine Product Portfolio
  84. 8.14.5 Benovus Bio Recent Developments
  85. 8.15 Artificial Cell Technologies
  86. 8.15.1 Artificial Cell Technologies Company Information
  87. 8.15.2 Artificial Cell Technologies Business Overview
  88. 8.15.3 Artificial Cell Technologies Synthetic Peptide Vaccine Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Artificial Cell Technologies Synthetic Peptide Vaccine Product Portfolio
  90. 8.15.5 Artificial Cell Technologies Recent Developments
  91. 8.16 Apitope Technology
  92. 8.16.1 Apitope Technology Company Information
  93. 8.16.2 Apitope Technology Business Overview
  94. 8.16.3 Apitope Technology Synthetic Peptide Vaccine Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 Apitope Technology Synthetic Peptide Vaccine Product Portfolio
  96. 8.16.5 Apitope Technology Recent Developments
  97. 8.17 Antigen Express
  98. 8.17.1 Antigen Express Company Information
  99. 8.17.2 Antigen Express Business Overview
  100. 8.17.3 Antigen Express Synthetic Peptide Vaccine Sales, Value and Gross Margin (2021-2026)
  101. 8.17.4 Antigen Express Synthetic Peptide Vaccine Product Portfolio
  102. 8.17.5 Antigen Express Recent Developments
  103. 8.18 Anergis
  104. 8.18.1 Anergis Company Information
  105. 8.18.2 Anergis Business Overview
  106. 8.18.3 Anergis Synthetic Peptide Vaccine Sales, Value and Gross Margin (2021-2026)
  107. 8.18.4 Anergis Synthetic Peptide Vaccine Product Portfolio
  108. 8.18.5 Anergis Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Synthetic Peptide Vaccine Value Chain Analysis
  2. 9.1.1 Synthetic Peptide Vaccine Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Synthetic Peptide Vaccine Sales Mode & Process
  6. 9.2 Synthetic Peptide Vaccine Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Synthetic Peptide Vaccine Distributors
  9. 9.2.3 Synthetic Peptide Vaccine Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst